Neurogene Inc. — Director's Dealing 2015

Feb 9, 2015

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: AQUINOX PHARMACEUTICALS, INC (AQXP)
CIK: 0001404644
Period of Report: 2014-12-31

Reporting Person: SHREWSBURY STEPHEN B (CMO; Senior VP Clinical Dev.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-09-02	Common Stock	P	400	$8.22	Acquired	400	Direct